Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetRevenue - OtherShort-Term Debt repayments
Ratios

Fortress Biotech (FBIO) R&D In Process (2016 - 2023)

Fortress Biotech has reported R&D In Process over the past 10 years, most recently at $31000.0 for Q4 2023.

  • Quarterly results put R&D In Process at $31000.0 for Q4 2023, down 95.07% from a year ago — trailing twelve months through Dec 2023 was $4.3 million (up 524.86% YoY), and the annual figure for FY2024 was $252000.0, down 94.17%.
  • R&D In Process for Q4 2023 was $31000.0 at Fortress Biotech, down from $60000.0 in the prior quarter.
  • Over the last five years, R&D In Process for FBIO hit a ceiling of $14.9 million in Q1 2020 and a floor of $1000.0 in Q2 2022.
  • Median R&D In Process over the past 5 years was $454000.0 (2019), compared with a mean of $2.2 million.
  • Peak annual rise in R&D In Process hit 4093.33% in 2022, while the deepest fall reached 99.99% in 2022.
  • Fortress Biotech's R&D In Process stood at $450000.0 in 2019, then rose by 16.0% to $522000.0 in 2020, then crashed by 97.13% to $15000.0 in 2021, then soared by 4093.33% to $629000.0 in 2022, then crashed by 95.07% to $31000.0 in 2023.
  • The last three reported values for R&D In Process were $31000.0 (Q4 2023), $60000.0 (Q3 2023), and $3000.0 (Q2 2023) per Business Quant data.